Analysis of frontal variant of Alzheimer's disease using molecular imaging and biofluid markers

Takeaway

  • An integrated approach combining neuropsychological tests, molecular neuroimaging, and biofluid biomarkers may help clinicians diagnose frontal variant of Alzheimer's disease (fvAD).

Why this matters

  • fvAD is a rare type of non-amnestic AD which has a similar clinical presentation to behavior variant of frontotemporal dementia (bvFTD), especially early on in the disease course. The clinical distinction between fvAD and bvFTD, highlighted by these findings, has implications for prognosis, treatment choices, and disease progression for those affected.